377 General Discussion - hiPSC-CMs Disease Modelling and Future Perspectives 13 48. Meier, A. B. et al. Epicardioid single-cell genomics uncovers principles of human epicardium biology in heart development and disease. Nat. Biotechnol. 41, 1787–1800 (2023). 49. Xiang, Y. et al. Fusion of Regionally Specified hPSC-Derived Organoids Models Human Brain Development and Interneuron Migration. Cell Stem Cell 21, (2017). 50. Meijer, E. M. et al. 3D Human iPSC Blood Vessel Organoids as a Source of Flow-Adaptive Vascular Cells for Creating a Human-Relevant 3D-Scaffold Based Macrovessel Model. Advanced biology 7, (2023). 51. Moriwaki, T. et al. Scalable production of homogeneous cardiac organoids derived from human pluripotent stem cells. Cell reports methods 3, (2023). 52. Noordzij, M. et al. Sample size calculations: basic principles and common pitfalls. Nephrol. Dial. Transplant 25, 1388–1393 (2010). 53. Challenges in designing and executing clinical trials in a dish studies. J. Pharmacol. Toxicol. Methods 94, 73–82 (2018). 54. Van Norman, G. A. Phase II Trials in Drug Development and Adaptive Trial Design. JACC. Basic to translational science 4, (2019). 55. Zushin, P.-J. H., Mukherjee, S. & Wu, J. C. FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches. J. Clin. Invest. 133, (2023). 56. Denning, C. et al. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform. Biochim. Biophys. Acta 1863, 1728–1748 (2016). 57. Comparison of 10 Control hPSC Lines for Drug Screening in an Engineered Heart Tissue Format. Stem Cell Reports 15, 983–998 (2020). 58. Juhola, M., Penttinen, K., Joutsijoki, H. & Aalto-Setälä, K. Analysis of Drug Effects on iPSC Cardiomyocytes with Machine Learning. Ann. Biomed. Eng. 49, 129 (2021). 59. HiPSC-CMs from different sex and ethnic origin donors exhibit qualitatively different responses to several classes of pharmacological challenges. J. Pharmacol. Toxicol. Methods 99, 106598 (2019). 60. Shinozawa, T. et al. Recapitulation of Clinical Individual Susceptibility to Drug-Induced QT Prolongation in Healthy Subjects Using iPSC-Derived Cardiomyocytes. Stem Cell Reports 8, 226 (2017). 61. Stillitano, F. et al. Modeling susceptibility to drug-induced long QT with a panel of subject-specific induced pluripotent stem cells. Elife 6, (2017). 62. Blinova, K. et al. Clinical Trial in a Dish: Personalized Stem Cell–Derived Cardiomyocyte Assay Compared With Clinical Trial Results for Two QT‐Prolonging Drugs. Clin. Transl. Sci. 12, 687 (2019). 63. Sharma, A. et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci. Transl. Med. 9, (2017). 64. Grimm, F. A. et al. A human population-based organotypic in vitro model for cardiotoxicity screening. ALTEX 35, 441 (2018). 65. Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons. Cell Rep. 39, 110643 (2022). 66. Juhola, M., Joutsijoki, H., Penttinen, K., Shah, D. & Aalto-Setälä, K. On computational classification of genetic cardiac diseases applying iPSC cardiomyocytes. Comput. Methods Programs Biomed. 210, (2021). 67. Willi, L. et al. Bioenergetic and Metabolic Impairments in Induced Pluripotent Stem Cell-Derived Cardiomyocytes Generated from Duchenne Muscular Dystrophy Patients. Int. J. Mol. Sci. 23, (2022). 68. Sun, N. et al. Patient-Specific Induced Pluripotent Stem Cell as a Model for Familial Dilated Cardiomyopathy. Sci. Transl. Med. 4, 130ra47 (2012). 69. Lan, F. et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12, (2013). 70. Carvalho, A. B. et al. Action potential variability in human pluripotent stem cell-derived cardiomyocytes obtained from healthy donors. Front. Physiol. 13, (2022). 71. McKeithan, W. L. et al. An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes. Front. Physiol. 8, 766 (2017). 72. Polonchuk, L. et al. Cardiac spheroids as promising in vitro models to study the human heart microenvironment. Sci. Rep. 7, (2017).
RkJQdWJsaXNoZXIy MTk4NDMw